These results suggested that these three common signature genes (PLCXD3, CCL19, and PKD2) and nomogram models can serve as effective diagnostic biomarkers for distinguishing advanced AS and NAFLD. Here, CCL19 is linked to metabolic dysfunction-associated steatotic liver disease.